The chemical class known as α4Gn-T, also known as A4GNT, activators encompasses a variety of compounds that can influence the activity of the enzyme alpha-1,4-N-acetylglucosaminyltransferase. Rather than acting as direct agonists, these chemicals can modify the cellular environment or the glycosylation pathways in which α4Gn-T operates. Their modes of action are diverse, reflecting the complex interplay between enzyme function and cellular processes. Some members of this class act by inhibiting other glycosylation pathways, which can lead to a compensatory increase in the activity of α4Gn-T as the cell attempts to maintain glycosylation homeostasis. Others interfere with the folding and processing of glycoproteins, which can indirectly upregulate the expression or activity of α4Gn-T as the cell responds to changes in glycoprotein structure and function.
Additionally, certain chemicals in this class are known to disrupt the function of the Golgi apparatus, where α4Gn-T is localized, thereby affecting its operation. Alterations in the Golgi apparatus can have broad implications for glycosylation enzymes, including α4Gn-T. Some activators work by influencing the cellular levels of key glycosylation substrates or by altering the signaling pathways that govern the expression of glycosylation enzymes. They can affect the availability of precursor molecules necessary for the enzymatic activity of α4Gn-T or modulate the intracellular signaling that regulates enzyme expression. Through these diverse actions, the chemicals classified as α4Gn-T activators can play a significant role in regulating the activity of this enzyme, thereby influencing the glycosylation patterns within the cell.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
Inhibitor of N-linked glycosylation; could possibly activate A4GNT as a compensatory mechanism when O-glycosylation is upregulated. | ||||||
Deoxynojirimycin | 19130-96-2 | sc-201369 sc-201369A | 1 mg 5 mg | $72.00 $142.00 | ||
Inhibitor of alpha-glucosidases; could possibly activate A4GNT by leading to glycoprotein misfolding and indirectly affecting function. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Adenylyl cyclase activator; raises intracellular cAMP levels, which could possibly activate glycosylation enzyme expression including A4GNT. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $65.00 $210.00 | 26 | |
Analog of glucose; can interfere with glycolysis and could possibly activate glycosylation processes related to A4GNT activity. | ||||||
Azaserine | 115-02-6 | sc-29063 sc-29063A | 50 mg 250 mg | $306.00 $906.00 | 15 | |
Glutamine antagonist; could possibly activate glycosylation by limiting substrate availability for glycan synthesis, possibly influencing A4GNT. | ||||||
Kifunensine | 109944-15-2 | sc-201364 sc-201364A sc-201364B sc-201364C | 1 mg 5 mg 10 mg 100 mg | $132.00 $529.00 $1005.00 $6125.00 | 25 | |
Mannosidase I inhibitor; could possibly activate A4GNT by increasing misfolded glycoproteins and altering the function of glycosylation enzymes. | ||||||